Hims & Hers Health Dirección
Dirección controles de criterios 2/4
El CEO de Hims & Hers Health es Andrew Dudum , nombrado en Jan 2017, tiene una permanencia de 7.83 años. compensación anual total es $14.40M, compuesta por 4.2% salario y 95.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 8.61% de las acciones de la empresa, por valor de $410.08M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 2.9 años, respectivamente.
Información clave
Andrew Dudum
Chief Executive Officer (CEO)
US$14.4m
Compensación total
| Porcentaje del salario del CEO | 4.2% |
| Permanencia del CEO | 7.8yrs |
| Participación del CEO | 8.6% |
| Permanencia media de la dirección | 2.7yrs |
| Promedio de permanencia en la Junta Directiva | 2.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$101m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Compensación vs. Mercado: La compensación total de Andrew($USD14.40M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.60M).
Compensación vs. Ingresos: La compensación de Andrew ha sido consistente con los resultados de la empresa en el último año.
CEO
Andrew Dudum (35 yo)
7.8yrs
Permanencia
US$14,401,411
Compensación
Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$14.40m | 8.61% $ 410.1m | |
| Chief Financial Officer | 2.8yrs | US$7.43m | 0.051% $ 2.4m | |
| Chief Operating Officer | 3.8yrs | US$6.77m | 0.29% $ 13.7m | |
| Chief Legal Officer & Corporate Secretary | 3.8yrs | US$5.21m | 0.077% $ 3.7m | |
| Chief Medical Officer | 1.9yrs | US$198.26k | 0.088% $ 4.2m | |
| Chief Commercial Officer | less than a year | US$6.71m | 0.084% $ 4.0m | |
| Senior VP | 5.4yrs | US$961.12k | 0.0023% $ 111.4k | |
| Chief Communications Officer | 1.1yrs | sin datos | sin datos | |
| Senior Vice President of Human Resources | 2.7yrs | sin datos | sin datos | |
| Senior VP & Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Chief Pharmacy & Innovation Officer | 1.9yrs | sin datos | sin datos | |
| Senior Vice President of Mental Health | 1.7yrs | sin datos | sin datos |
2.7yrs
Permanencia media
44yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HIMS se considera experimentado (2.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 3.8yrs | US$14.40m | 8.61% $ 410.1m | |
| Chief Medical Officer | 2.8yrs | US$198.26k | 0.088% $ 4.2m | |
| Senior VP & Member of Medical Advisory Board | 2.8yrs | sin datos | sin datos | |
| Independent Director | 4.2yrs | US$194.26k | 0.025% $ 1.2m | |
| Lead Independent Director | 4.2yrs | US$227.41k | 0.071% $ 3.4m | |
| Independent Director | 3.7yrs | US$205.51k | 0.033% $ 1.6m | |
| Member of Medical Advisory Board | 2.9yrs | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | 2.9yrs | sin datos | sin datos | |
| Member of Medical Advisory Board | 2.9yrs | sin datos | sin datos | |
| Member of Medical Advisory Board | 2.9yrs | sin datos | sin datos | |
| Member of Medical Advisory Board | 2.9yrs | sin datos | sin datos |
2.9yrs
Permanencia media
53yo
Promedio de edad
Junta con experiencia: La junta directiva de HIMS no se considera experimentada (2.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.